TP53 and adenocarcinoma: TP53 (67/91, 73.6%) was the most frequently mutated gene in all these NSCLC patients, which was mutated in 100% (32/32) of squamous cell carcinoma (SqCC) patients compared to 60.7% (34/56) in adenocarcinoma (AD).